Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations

NCT04512430 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT04512430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04512430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Terminated
Start date
December 2, 2020
Completion date
July 19, 2024
Enrollment
4 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, non small cell lung cancer